🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the fight against superbug strains of the pathogen, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are escalating around the world, with data suggesting over 82 million infections annually. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, also known as a brand name, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in concurrent days. This treatment, which is also used to treat UTIs, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm Innoviva to bring it to fruition.

“This milestone represents a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Outcomes and Worldwide Availability

As per results detailed in a major medical journal, the new drug cured the vast majority of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The trial involved hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced optimism. The availability of a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is deemed vital to lessen the impact of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.